ChemPartner PharmaTech Co.,Ltd. (SHE:300149)
China
· Delayed Price · Currency is CNY 10.00
-0.60 (-5.66%)
At close: Apr 29, 2026
ChemPartner PharmaTech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 1,135 | 965.1 | 1,132 | 1,321 | 1,685 | Upgrade
|
| Other Revenue | - | 5.1 | 6.5 | 5.54 | 6.16 | Upgrade
|
| Revenue | 1,135 | 970.2 | 1,138 | 1,327 | 1,691 | Upgrade
|
| Revenue Growth (YoY) | 16.96% | -14.77% | -14.19% | -21.54% | 14.11% | Upgrade
|
| Cost of Revenue | 810.03 | 768.13 | 859.37 | 999.55 | 1,158 | Upgrade
|
| Gross Profit | 324.69 | 202.07 | 279 | 327.04 | 532.22 | Upgrade
|
| Selling, General & Admin | 233.37 | 203.62 | 256.78 | 306.24 | 331.24 | Upgrade
|
| Research & Development | 59.84 | 59.55 | 77.47 | 92.28 | 124.65 | Upgrade
|
| Other Operating Expenses | -7.62 | 4.92 | 5.66 | 7.48 | 5.69 | Upgrade
|
| Operating Expenses | 285.6 | 299.33 | 344.57 | 422.6 | 466.91 | Upgrade
|
| Operating Income | 39.1 | -97.26 | -65.57 | -95.56 | 65.31 | Upgrade
|
| Interest Expense | - | -26.1 | -31.3 | -66.48 | -78.73 | Upgrade
|
| Interest & Investment Income | 12.15 | 22.25 | 14.79 | 1,403 | 14.72 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 10.88 | 3.52 | 44.05 | -6.12 | Upgrade
|
| Other Non Operating Income (Expenses) | -38.37 | -1.05 | -2.41 | -3.5 | 1.11 | Upgrade
|
| EBT Excluding Unusual Items | 12.89 | -91.28 | -80.97 | 1,281 | -3.71 | Upgrade
|
| Impairment of Goodwill | - | -139.26 | -816.73 | -232.4 | -367.6 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -2.3 | -0.92 | -0.04 | 0.06 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.04 | 8.43 | -0 | -0.15 | -0.02 | Upgrade
|
| Asset Writedown | 3.17 | -21.49 | -50.45 | -312.89 | -5.67 | Upgrade
|
| Other Unusual Items | - | 14.25 | 9.3 | 8.85 | 15.91 | Upgrade
|
| Pretax Income | 16.01 | -231.64 | -939.77 | 744.72 | -361.03 | Upgrade
|
| Income Tax Expense | 2.46 | -5.13 | -22.83 | 366.34 | 41.07 | Upgrade
|
| Earnings From Continuing Operations | 13.55 | -226.51 | -916.94 | 378.38 | -402.1 | Upgrade
|
| Minority Interest in Earnings | -0.14 | 0.04 | 0.19 | 0.21 | -0.15 | Upgrade
|
| Net Income | 13.41 | -226.47 | -916.75 | 378.59 | -402.25 | Upgrade
|
| Net Income to Common | 13.41 | -226.47 | -916.75 | 378.59 | -402.25 | Upgrade
|
| Shares Outstanding (Basic) | 447 | 503 | 498 | 498 | 497 | Upgrade
|
| Shares Outstanding (Diluted) | 447 | 503 | 498 | 498 | 497 | Upgrade
|
| Shares Change (YoY) | -11.17% | 1.01% | 0.02% | 0.31% | -0.64% | Upgrade
|
| EPS (Basic) | 0.03 | -0.45 | -1.84 | 0.76 | -0.81 | Upgrade
|
| EPS (Diluted) | 0.03 | -0.45 | -1.84 | 0.76 | -0.81 | Upgrade
|
| Free Cash Flow | 128.03 | 98.96 | -50.3 | -73.74 | 92.22 | Upgrade
|
| Free Cash Flow Per Share | 0.29 | 0.20 | -0.10 | -0.15 | 0.19 | Upgrade
|
| Gross Margin | 28.62% | 20.83% | 24.51% | 24.65% | 31.48% | Upgrade
|
| Operating Margin | 3.45% | -10.03% | -5.76% | -7.20% | 3.86% | Upgrade
|
| Profit Margin | 1.18% | -23.34% | -80.53% | 28.54% | -23.79% | Upgrade
|
| Free Cash Flow Margin | 11.28% | 10.20% | -4.42% | -5.56% | 5.46% | Upgrade
|
| EBITDA | 91.14 | -39.39 | -2.48 | 14.67 | 176.97 | Upgrade
|
| EBITDA Margin | 8.03% | -4.06% | -0.22% | 1.10% | 10.47% | Upgrade
|
| D&A For EBITDA | 52.05 | 57.87 | 63.1 | 110.23 | 111.66 | Upgrade
|
| EBIT | 39.1 | -97.26 | -65.57 | -95.56 | 65.31 | Upgrade
|
| EBIT Margin | 3.45% | -10.02% | -5.76% | -7.20% | 3.86% | Upgrade
|
| Effective Tax Rate | 15.36% | - | - | 49.19% | - | Upgrade
|
| Revenue as Reported | - | 970.2 | 1,138 | 1,327 | 1,691 | Upgrade
|
| Advertising Expenses | - | 0.47 | 0.73 | 0.68 | 0.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.